Renal ultrasonography predicts worsening renal function in patients with heart failure under tolvaptan administration.

Autor: Tanaka N; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan., Furukawa Y; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan., Maeda T; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan., Ishihara H; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan., Dan K; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan., Teramura M; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan., Ichihashi K; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan., Takase T; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan., Takahashi Y; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan., Tsuzura D; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan., Shinoda A; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan., Fujii M; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan., Okada H; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan., Itabashi F; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan., Teramoto T; Department of Cardiovascular Medicine, Ichinomiya Nishi Hospital, 1 Kaimei-hira, Ichinomiya, 494-0001, Japan.
Jazyk: angličtina
Zdroj: ESC heart failure [ESC Heart Fail] 2024 Aug; Vol. 11 (4), pp. 1911-1918. Date of Electronic Publication: 2024 Mar 12.
DOI: 10.1002/ehf2.14740
Abstrakt: Aims: Renal dysfunction in patients with chronic heart failure predicts a poor prognosis. Tolvaptan has a diuretic effect in patients with chronic kidney disease and heart failure without adverse effects on renal function. We aimed to determine the effects of tolvaptan and predictors of worsening renal function in patients with heart failure.
Methods and Results: This post hoc analysis was a sub-analysis of a single-centre prospectively randomized trial on the early and short-term tolvaptan administration. We enrolled 201 participants with decompensated heart failure between January 2014 and March 2019 (early group, n = 104; age: 79.0 ± 12.8 years; late group, n = 97; age: 80.3 ± 10.8 years). Renal ultrasonography was performed before and after the administration of tolvaptan. Urine output and oral water intake significantly increased during tolvaptan administration. The difference between water intake and urine volume increased during tolvaptan administration. Changes in body weight, blood pressure, heart rate, and estimated glomerular filtration rate (eGFR) in both groups were comparable. The changes in peak-systolic velocity (PSV), acceleration time (AT) of the renal arteries, and resistance index were comparable. The changes in PSV and end-diastolic velocity (EDV) of the interlobar arteries increased following tolvaptan administration (Δmax PSV: 0.0 ± 14.8 cm/s before tolvaptan vs. 5.6 ± 15.7 cm/s after tolvaptan, P = 0.002; Δmean PSV: 0.4 ± 12.3 vs. 4.9 ± 12.7 cm/s, P = 0.002; Δmax EDV: -0.2 ± 3.5 vs. 1.4 ± 4.0 cm/s, P = 0.001; Δmean EDV: -0.0 ± 3.1 vs. 1.1 ± 3.4 cm/s, P = 0.003). The renal artery AT was negatively correlated with the eGFR (Δmax AT: beta = -0.2354, P = 0.044; Δmean AT: beta = -0.2477, P = 0.035).
Conclusions: Tolvaptan increased the PSV and EDV of the interlobar artery, which may mean tolvaptan increased renal blood flow. The renal artery AT may be a surrogate for worsening renal function.
(© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
Databáze: MEDLINE
Externí odkaz: